REV-ERB agonist is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-27. Numbers and descriptions here follow the published literature rather than marketing material.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Small-molecule nuclear receptor ligand |
| Appearance | Off-white to pale yellow solid | Typical for research-grade powder |
| Solubility class | Soluble in DMSO; low water solubility | Common stock solutions use organic solvent |
| Typical stock solvent | Dimethyl sulfoxide | Used for laboratory assays |
| Common analytical method | HPLC with UV or mass detection | Used for identity and purity checks |
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
MS2 tagging is a technique based upon the natural interaction of the MS2 bacteriophage coat protein with a stem-loop structure from the phage genome, which is used for biochemical purification of RNA-protein complexes and partnered to GFP for detection of RNA in living cells. More recently, the technique has been used to monitor the appearance of RNA in living cells, at the site of transcription, or simply by observing the changes in RNA number in the cytoplasm. This has revealed that transcription of both prokaryotic and eukaryotic genes occurs in a discontinuous fashion with bursts of transcription separated by irregular intervals.
Roberto Gottardo of the diocese of Turin stated that for the first time they had released high-definition images of the Shroud that can be used on tablet computers and can be magnified to show details not visible to the naked eye. As this rare exposition took place, Pope Francis issued a carefully worded statement which urged the faithful to contemplate the Shroud with awe but, like most of his predecessors, he "stopped firmly short of asserting its authenticity". The Shroud was again placed on display in the cathedral in Turin from 19 April 2015 to 24 June 2015. There was no charge to view it, but an appointment was required.
== Further reading == Videos "Why Is McDonald's Struggling In The Philippines? Jollibee". CNBC. November 20, 2018. Archived from the original on November 6, 2021. "Jollibee CEO on the homegrown fast food giant's growing appetite for acquisitions". CNBC International TV. May 7, 2019. Archived from the original on October 2, 2020. Retrieved May 7, 2019.{{cite web}}: CS1 maint: bot: original URL status unknown (link) "Why Jollibee's Fast Food has Americans Waiting in Insane Lines — Cult Following". Eater/Vox Media. April 13, 2017. Archived from the original on November 6, 2021. "Jollibee: How it became one of the world's biggest Asian fast food companies". South China Morning Post. July 20, 2019. Archived from the original on November 6, 2021.
Hood's research group corrected the neurological defect in mice (the shiverer defect) by transferring a normal MBP gene into the fertilized egg of the shiverer mouse. These discoveries led to extensive studies of MBP and its biology.
Sources: en.wikipedia.org
Following the November 2008 terrorist attacks in Mumbai, Hitchens argued in a radio interview with Hugh Hewitt that Pakistan's Inter-Services Intelligence (ISI) bore substantial responsibility for the attacks and pressed for the United States to realign its South Asia policy away from Pakistan and more firmly toward India. He stated that Pakistan had used militant groups as proxies "to colonize Afghanistan" and to apply "strategic depth against India in Kashmir," and described Pakistan as a "rogue, failed state."
Critical Reviews in Clinical Laboratory Sciences is a peer-reviewed medical journal that publishes review articles on all aspects of clinical laboratory sciences on an invitation-only basis. The journal is published by Taylor and Francis and the editor-in-chief is Khosrow Adeli (University of Toronto). According to the Journal Citation Reports, the journal has a 2019 impact factor of 4.677.
== Overview == Neuland operates through two primary business verticals: Generic Drug Substances (GDS) and CDMO services. Its operations span process research and development, custom synthesis, scale-up, regulatory documentation support, and commercial manufacturing. The company exports products to more than 80 countries and maintains approvals from major international regulatory authorities, including the United States Food and Drug Administration (US FDA), European Directorate for the Quality of Medicines (EDQM), and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA). As of 2026, Neuland employs approximately 2,000 people, including over 360 scientists engaged in research and development activities. For the full financial year 2026, the company surpassed ₹2000 crore in total revenue for the first time (approximately US $215 million. In the fourth quarter of FY2026, EBITDA increased by nearly 449% year-on-year to 319.4 crore (US$33 million), with an EBITDA margin of 40%. Profit after tax for the quarter stood at ₹212.5 crore (approximately US$22 million)
=== NSAIDs === Nonsteroidal anti-inflammatory drugs (NSAIDs) and alcohol both increase gastrointestinal events such as gastrointestinal bleeding and peptic ulcers. Taking the two together further increases the risk additively. The risk of stomach bleeding is still increased when aspirin is taken with alcohol or warfarin.
== Biosynthesis == Biosynthesis of bleomycin is completed by glycosylation of the aglycones. Bleomycin naturally occurring-analogues have two to three sugar molecules, and DNA cleavage activities of these analogues have been assessed, primarily by the plasmid relaxation and break light assays.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that acts on REV-ERB nuclear receptors. It is not approved for human use and is sold only as a research chemical. Its effects have been studied mainly in cells and rodents.
It binds REV-ERB alpha and REV-ERB beta and changes the expression of genes tied to metabolism and circadian rhythm. These changes can affect mitochondria and energy use in animal models. The exact chain from receptor binding to physiological outcome is still being mapped.
No reliable human trials show that SR9009 improves athletic performance. Some rodent studies report endurance changes, but these results are not proof of human benefit. Its use in sport is prohibited, and quality and safety data are lacking.
Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.